Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):958–963. doi: 10.1128/aac.39.4.958

Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.

S S Park 1, D J D'Amico 1, B Paton 1, A S Baker 1
PMCID: PMC162661  PMID: 7786003

Abstract

We investigated the efficacy of oral fluconazole, alone or in combination with oral flucytosine (5FC), in treating Candida endophthalmitis using a rabbit model. Albino rabbits were infected with an intravitreal inoculation of 1,000 CFU of susceptible Candida albicans and randomized 5 days later to receive treatment with oral fluconazole alone (80 mg/kg of body weight per day), a combination of fluconazole and 5FC (100 mg/kg/12 h), or no treatment. The treatment effect was assessed at 2 and 4 weeks after therapy by funduscopy, quantitative vitreous culture, and histopathology. Intravitreal levels of fluconazole, 2 to 24 h after the first dose, were measured to be > 10 times the MIC of the drug for C. albicans. Among rabbits treated with fluconazole for 2 weeks, 67% had a > 90% reduction in fungal load (P < 0.05) and 33% were sterile. After 4 weeks, all had a > 99% reduction in fungal load (P < 0.05) and 75% were sterile (P = 0.01). This treatment effect was unchanged 4 weeks after discontinuation of fluconazole. Among rabbits treated with fluconazole and 5FC for 2 weeks, 67% died during therapy. Among the surviving rabbits, 75% had a > 90% reduction in fungal load (P < 0.05) and 25% were sterile. We conclude that oral fluconazole may be useful for treatment of Candida endophthalmitis. Addition of 5FC was associated with high toxicity and minimal additional antifungal effect in our rabbit model.

Full Text

The Full Text of this article is available as a PDF (212.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar G. L., Blumenkrantz M. S., Egbert P. R., McCulley J. P. Candida endophthalmitis after intravenous drug abuse. Arch Ophthalmol. 1979 Jan;97(1):96–100. doi: 10.1001/archopht.1979.01020010036008. [DOI] [PubMed] [Google Scholar]
  2. Allendoerfer R., Marquis A. J., Rinaldi M. G., Graybill J. R. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1991 Apr;35(4):726–729. doi: 10.1128/aac.35.4.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennet J. E. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. doi: 10.7326/0003-4819-86-3-319. [DOI] [PubMed] [Google Scholar]
  4. Berry A. J., Rinaldi M. G., Graybill J. R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992 Mar;36(3):690–692. doi: 10.1128/aac.36.3.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bodet C. A., 3rd, Jorgensen J. H., Drutz D. J. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985 Aug;22(2):157–160. doi: 10.1128/jcm.22.2.157-160.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Borne M. J., Elliott J. H., O'Day D. M. Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol. 1993 Oct;111(10):1326–1327. doi: 10.1001/archopht.1993.01090100032019. [DOI] [PubMed] [Google Scholar]
  7. Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S318–S326. doi: 10.1093/clinids/12.supplement_3.s318. [DOI] [PubMed] [Google Scholar]
  8. Brod R. D., Flynn H. W., Jr, Clarkson J. G., Pflugfelder S. C., Culbertson W. W., Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology. 1990 May;97(5):666–674. doi: 10.1016/s0161-6420(90)32547-2. [DOI] [PubMed] [Google Scholar]
  9. Coats M. L., Peyman G. A. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina. 1992;12(1):46–51. doi: 10.1097/00006982-199212010-00010. [DOI] [PubMed] [Google Scholar]
  10. Cruciani M., Di Perri G., Concia E., Bassetti D., Bonora A., Mecca E., Panozzo G., Tomazzoli L. Fluconazole and fungal ocular infection. J Antimicrob Chemother. 1990 Apr;25(4):718–720. doi: 10.1093/jac/25.4.718. [DOI] [PubMed] [Google Scholar]
  11. Diaz M., Negroni R., Montero-Gei F., Castro L. G., Sampaio S. A., Borelli D., Restrepo A., Franco L., Bran J. L., Arathoon E. G. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S68–S76. doi: 10.1093/clinids/14.supplement_1.s68. [DOI] [PubMed] [Google Scholar]
  12. Dunn E. T., Mansour A. M. Retinal striae as a sign of resolving candidal chorioretinitis. Graefes Arch Clin Exp Ophthalmol. 1988;226(6):591–592. doi: 10.1007/BF02169210. [DOI] [PubMed] [Google Scholar]
  13. Edwards J. E., Jr, Foos R. Y., Montgomerie J. Z., Guze L. B. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore) 1974 Jan;53(1):47–75. doi: 10.1097/00005792-197401000-00002. [DOI] [PubMed] [Google Scholar]
  14. Elliott J. H., O'Day D. M., Gutow G. S., Podgorski S. F., Akrabawi P. Mycotic endophthalmitis in drug abusers. Am J Ophthalmol. 1979 Jul;88(1):66–72. doi: 10.1016/0002-9394(79)90757-8. [DOI] [PubMed] [Google Scholar]
  15. Filler S. G., Crislip M. A., Mayer C. L., Edwards J. E., Jr Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother. 1991 Feb;35(2):288–292. doi: 10.1128/aac.35.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fisher M. A., Shen S. H., Haddad J., Tarry W. F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989 Sep;33(9):1443–1446. doi: 10.1128/aac.33.9.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Francis P., Walsh T. J. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992 Dec;15(6):1003–1018. doi: 10.1093/clind/15.6.1003. [DOI] [PubMed] [Google Scholar]
  18. Griffin J. R., Pettit T. H., Fishman L. S., Foos R. Y. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch Ophthalmol. 1973 Jun;89(6):450–456. doi: 10.1001/archopht.1973.01000040452002. [DOI] [PubMed] [Google Scholar]
  19. Harris S. C., Wallace J. E., Foulds G., Rinaldi M. G. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989 May;33(5):714–716. doi: 10.1128/aac.33.5.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Heinemann M. H., Bloom A. F., Horowitz J. Candida albicans endophthalmitis in a patient with AIDS. Case report. Arch Ophthalmol. 1987 Sep;105(9):1172–1173. doi: 10.1001/archopht.1987.01060090030012. [DOI] [PubMed] [Google Scholar]
  21. Henderson D. K., Edwards J. E., Jr, Montgomerie J. Z. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis. 1981 May;143(5):655–661. doi: 10.1093/infdis/143.5.655. [DOI] [PubMed] [Google Scholar]
  22. Jones D. B., Green M. T., Osato M. S., Broberg P. H., Gentry L. O. Endogenous Candida albicans endophthalmitis in the rabbit. Chemotherapy for systemic effect. Arch Ophthalmol. 1981 Dec;99(12):2182–2187. doi: 10.1001/archopht.1981.03930021058014. [DOI] [PubMed] [Google Scholar]
  23. Kowalsky S. F., Dixon D. M. Fluconazole: a new antifungal agent. Clin Pharm. 1991 Mar;10(3):179–194. [PubMed] [Google Scholar]
  24. Laatikainen L., Tuominen M., von Dickhoff K. Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol. 1992 Feb 15;113(2):205–207. doi: 10.1016/s0002-9394(14)71537-5. [DOI] [PubMed] [Google Scholar]
  25. Maxwell D. P., Jr, Brent B. D., Diamond J. G., Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology. 1991 Sep;98(9):1370–1375. doi: 10.1016/s0161-6420(91)32108-0. [DOI] [PubMed] [Google Scholar]
  26. Mori T., Matsumura M., Ebe T., Takahashi M., Kohara T., Inagaki M., Isonuma H., Hibiya I., Hamamoto T., Watanabe K. [Fluconazole treatment of systemic mycoses]. Jpn J Antibiot. 1989 Jan;42(1):55–62. [PubMed] [Google Scholar]
  27. Nomura J., Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin Infect Dis. 1993 Nov;17(5):888–889. doi: 10.1093/clinids/17.5.888. [DOI] [PubMed] [Google Scholar]
  28. O'Day D. M., Foulds G., Williams T. E., Robinson R. D., Allen R. H., Head W. S. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990 Jul;108(7):1006–1008. doi: 10.1001/archopht.1990.01070090108050. [DOI] [PubMed] [Google Scholar]
  29. O'Day D. M., Head W. S., Robinson R. D., Stern W. H., Freeman J. M. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985 Feb;4(2):131–134. doi: 10.3109/02713688508999978. [DOI] [PubMed] [Google Scholar]
  30. Perfect J. R. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S299–S302. doi: 10.1093/clinids/12.supplement_3.s299. [DOI] [PubMed] [Google Scholar]
  31. Robinson P. A., Knirsch A. K., Joseph J. A. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S349–S363. doi: 10.1093/clinids/12.supplement_3.s349. [DOI] [PubMed] [Google Scholar]
  32. Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Grieco M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83–89. doi: 10.1056/NEJM199201093260202. [DOI] [PubMed] [Google Scholar]
  33. Savani D. V., Perfect J. R., Cobo L. M., Durack D. T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. doi: 10.1128/aac.31.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Van't Wout J. W., Mattie H., van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother. 1988 May;21(5):665–672. doi: 10.1093/jac/21.5.665. [DOI] [PubMed] [Google Scholar]
  35. Walsh A., Haft D. A., Miller M. H., Loran M. R., Friedman A. H. Ocular penetration of 5-fluorocytosine. Invest Ophthalmol Vis Sci. 1978 Jul;17(7):691–694. [PubMed] [Google Scholar]
  36. Walsh T. J., Lee J., Aoki S., Mechinaud F., Bacher J., Lecciones J., Thomas V., Rubin M., Pizzo P. A. Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S307–S317. doi: 10.1093/clinids/12.supplement_3.s307. [DOI] [PubMed] [Google Scholar]
  37. del Palacio A., Cuétara M. S., Ferro M., Pérez-Blazquez E., López-Saña J. A., Roiz M. P., Carnevali D., Noriega A. R. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses. 1993 May-Jun;36(5-6):193–199. doi: 10.1111/j.1439-0507.1993.tb00749.x. [DOI] [PubMed] [Google Scholar]
  38. van Etten E. W., van de Rhee N. E., van Kampen K. M., Bakker-Woudenberg I. A. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother. 1991 Nov;35(11):2275–2281. doi: 10.1128/aac.35.11.2275. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES